Clinical Cancer Research, Vol 4, Issue 10 2433-2437, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Frequency of germline and somatic BRCA1 mutations in ovarian cancer

A Berchuck, KA Heron, ME Carney, JM Lancaster, EG Fraser, VL Vinson, AM Deffenbaugh, A Miron, JR Marks, PA Futreal and TS Frank
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA.

Germline mutations in the BRCA1 tumor suppressor gene are thought to be the most common cause of hereditary ovarian cancer. The aim of this study was to explore further the role of BRCA1 alterations in the development of ovarian cancers. We sought to determine whether somatic BRCA1 mutations are ever present in ovarian cancers and whether mutation is always accompanied by loss of the wild-type allele. The entire coding region and intronic splice sites of BRCA1 were sequenced using genomic DNA samples from 103 unselected ovarian cancers. Thirteen clearly deleterious BRCA1 mutations and two variants of uncertain significance were found. Blood DNA was available in all but two cases and demonstrated that 4 of 13 mutations and both variants of uncertain significance were germline alterations, whereas in seven cases the mutation was a somatic change present only in the cancer. Using four microsatellite markers, loss of heterozygosity at the BRCA1 locus was found in all 15 ovarian cancers with BRCA1 sequence alterations, compared with only 58% of ovarian cancers that did not have BRCA1 mutations. BRCA1-associated ovarian cancers were characterized by serous histology and moderate histological grade. These data confirm prior reports suggesting that germline mutations in BRCA1 are present in about 5% of women with ovarian cancer. In addition, somatic mutations in BRCA1 occur in the development of some sporadic cases. The finding that both germline and somatic BRCA1 mutations are accompanied by loss of heterozygosity, suggests that loss of this tumor suppressor gene is a critical event in the development of these cancers.

This article has been cited by other articles:

				J. I. Weberpals, K. V. Clark-Knowles, and B. C. Vanderhyden Sporadic Epithelial Ovarian Cancer: Clinical Relevance of BRCA1 Inhibition in the DNA Damage and Repair Pathway J. Clin. Oncol., July 1, 2008; 26(19): 3259 - 3267. [Abstract] [Full Text] [PDF]

				J. G. Guillem, W. C. Wood, J. F. Moley, A. Berchuck, B. Y. Karlan, D. G. Mutch, R. F. Gagel, J. Weitzel, M. Morrow, B. L. Weber, et al. ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes J. Clin. Oncol., October 1, 2006; 24(28): 4642 - 4660. [Abstract] [Full Text] [PDF]

				J. G. Guillem, W. C. Wood, J. F. Moley, A. Berchuck, B. Y. Karlan, D. G. Mutch, R. F. Gagel, J. Weitzel, M. Morrow, B. L. Weber, et al. ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes Ann. Surg. Oncol., October 1, 2006; 13(10): 1296 - 1321. [Abstract] [Full Text] [PDF]

				C M Phelan, V Dapic, B Tice, R Favis, E Kwan, F Barany, S Manoukian, P Radice, R B van der Luijt, B P M van Nesselrooij, et al. Classification of BRCA1 missense variants of unknown clinical significance J. Med. Genet., February 1, 2005; 42(2): 138 - 146. [Abstract] [Full Text] [PDF]

				P. M. Gilmore, N. McCabe, J. E. Quinn, R. D. Kennedy, J. J. Gorski, H. N. Andrews, S. McWilliams, M. Carty, P. B. Mullan, W. P. Duprex, et al. BRCA1 Interacts with and Is Required for Paclitaxel-Induced Activation of Mitogen-Activated Protein Kinase Kinase Kinase 3 Cancer Res., June 15, 2004; 64(12): 4148 - 4154. [Abstract] [Full Text] [PDF]

				N. Mirkovic, M. A. Marti-Renom, B. L. Weber, A. Sali, and A. N. A. Monteiro Structure-Based Assessment of Missense Mutations in Human BRCA1: Implications for Breast and Ovarian Cancer Predisposition Cancer Res., June 1, 2004; 64(11): 3790 - 3797. [Abstract] [Full Text] [PDF]

				S. R. Lakhani, S. Manek, F. Penault-Llorca, A. Flanagan, L. Arnout, S. Merrett, L. McGuffog, D. Steele, P. Devilee, J. G. M. Klijn, et al. Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers Clin. Cancer Res., April 1, 2004; 10(7): 2473 - 2481. [Abstract] [Full Text] [PDF]

				I. A. Hedenfalk Gene Expression Profiling of Hereditary and Sporadic Ovarian Cancers Reveals Unique BRCA1 and BRCA2 Signatures J Natl Cancer Inst, July 3, 2002; 94(13): 960 - 961. [Full Text] [PDF]

				A. A. Jazaeri, C. J. Yee, C. Sotiriou, K. R. Brantley, J. Boyd, and E. T. Liu Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers J Natl Cancer Inst, July 3, 2002; 94(13): 990 - 1000. [Abstract] [Full Text] [PDF]

				R. E. Buller, M. S. Shahin, J. P. Geisler, M. Zogg, B. R. De Young, and C. S. Davis Failure of BRCA1 Dysfunction to Alter Ovarian Cancer Survival Clin. Cancer Res., May 1, 2002; 8(5): 1196 - 1202. [Abstract] [Full Text] [PDF]

				J. P. Geisler, M. A. Hatterman-Zogg, J. A. Rathe, and R. E. Buller Frequency of BRCA1 Dysfunction in Ovarian Cancer J Natl Cancer Inst, January 2, 2002; 94(1): 61 - 67. [Abstract] [Full Text] [PDF]

				D. P. Harkin Uncovering Functionally Relevant Signaling Pathways Using Microarray-Based Expression Profiling Oncologist, December 1, 2000; 5(6): 501 - 507. [Abstract] [Full Text]

				M. Esteller, J. M. Silva, G. Dominguez, F. Bonilla, X. Matias-Guiu, E. Lerma, E. Bussaglia, J. Prat, I. C. Harkes, E. A. Repasky, et al. Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors J Natl Cancer Inst, April 5, 2000; 92(7): 564 - 569. [Abstract] [Full Text] [PDF]

				R. T. Penson, M. V. Seiden, K. M. Shannon, M. L. Lubratovich, M. Roche, B. A. Chabner, and T. J. Lynch Jr. Communicating Genetic Risk: Pros, Cons, and Counsel Oncologist, April 1, 2000; 5(2): 152 - 161. [Abstract] [Full Text]

				M. de la Hoya, E. Diaz-Rubio, and T. Caldes Denaturing Gradient Gel Electrophoresis-based Analysis of Loss of Heterozygosity Distinguishes Nonobvious, Deleterious BRCA1 Variants from Nonpathogenic Polymorphisms Clin. Chem., November 1, 1999; 45(11): 2028 - 2030. [Full Text] [PDF]